Contact
searchSearch
HMP Global
Login

Small-Cell Lung Cancer Specialty Channel

News
Lurbinectedin Demonstrates Promise As Second-Line Option for Patients With Platinum-Sensitive Small Cell Lung Cancer
12/18/2024
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results...
12/18/2024
Oncology
News
Chemoimmunotherapy Demonstrates Real-World Long-Term Efficacy for Patients With Extensive-Stage Small Cell Lung Cancer
12/10/2024
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a...
12/10/2024
Oncology
FDA Alerts
FDA Approves Durvalumab for Patients With Limited-Stage Small Cell Lung Cancer
12/05/2024
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the...
12/05/2024
Oncology
News
Addition of Talazoparib to Maintenance Atezolizumab Improves Survival Outcomes for Patients With SLFN11-Positive Extensive-Stage Small Cell Lung Cancer
12/04/2024
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results...
12/04/2024
Oncology
News
Addition of Toripalimab to First-Line Chemotherapy Improves Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/19/2024
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3...
11/19/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/04/2024
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a...
11/04/2024
Oncology
News
Adjuvant Durvalumab Significantly Extends Survival Among Patients With Limited-Stage Small Cell Lung Cancer
10/23/2024
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the...
10/23/2024
Oncology
Conference Coverage
Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
10/09/2024
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis...
10/09/2024
Oncology
Sally Lau, MD
Videos
Tarlatamab Plus PD-L1 Inhibitor as Potential First-Line Maintenance for Extensive-Stage Small Cell Lung Cancer
10/08/2024
Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.
Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.
Sally Lau, MD, discusses results...
10/08/2024
Oncology
Conference Coverage
Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer
10/01/2024
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis...
10/01/2024
Oncology

News

News
Lurbinectedin Demonstrates Promise As Second-Line Option for Patients With Platinum-Sensitive Small Cell Lung Cancer
12/18/2024
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results...
12/18/2024
Oncology
News
Chemoimmunotherapy Demonstrates Real-World Long-Term Efficacy for Patients With Extensive-Stage Small Cell Lung Cancer
12/10/2024
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a...
12/10/2024
Oncology
FDA Alerts
FDA Approves Durvalumab for Patients With Limited-Stage Small Cell Lung Cancer
12/05/2024
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the...
12/05/2024
Oncology
News
Addition of Talazoparib to Maintenance Atezolizumab Improves Survival Outcomes for Patients With SLFN11-Positive Extensive-Stage Small Cell Lung Cancer
12/04/2024
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results...
12/04/2024
Oncology
News
Addition of Toripalimab to First-Line Chemotherapy Improves Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/19/2024
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3...
11/19/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/04/2024
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a...
11/04/2024
Oncology
News
Adjuvant Durvalumab Significantly Extends Survival Among Patients With Limited-Stage Small Cell Lung Cancer
10/23/2024
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the...
10/23/2024
Oncology
Conference Coverage
Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
10/09/2024
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis...
10/09/2024
Oncology
Conference Coverage
Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer
10/01/2024
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis...
10/01/2024
Oncology

Interactive Features

FDA Alerts
FDA Approves Durvalumab for Patients With Limited-Stage Small Cell Lung Cancer
12/05/2024
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the...
12/05/2024
Oncology
Quiz
Quiz: Standard of Care for Patients With Small Cell Lung Cancer
11/30/2022
What is the current treatment for patients with small cell lung cancer?
What is the current treatment for patients with small cell lung cancer?
What is the current treatment...
11/30/2022
Oncology
Quiz
True or False: Median PFS of patients with SCLC with inflamed tumors receiving ICI and chemotherapy double that of patients with noninflamed tumors.
11/09/2022
According to a retrospective study, how did the median PFS of patients with extensive stage SCLC receiving immune checkpoint inhibition and chemotherapy who had inflamed tumors compare to those patients with noninflamed tumors?
According to a retrospective study, how did the median PFS of patients with extensive stage SCLC receiving immune checkpoint inhibition and chemotherapy who had inflamed tumors compare to those patients with noninflamed tumors?
According to a retrospective...
11/09/2022
Oncology
Quiz
True or False: PD-1 and PD-L1 inhibitors can be utilized as treatment in almost all stages of small-cell lung cancer (SCLC)?
09/30/2022
Can PD-1 and PD-L1 inhibitors be used to treat small-cell lung cancer in addition to non-small cell lung cancer?
Can PD-1 and PD-L1 inhibitors be used to treat small-cell lung cancer in addition to non-small cell lung cancer?
Can PD-1 and PD-L1 inhibitors be...
09/30/2022
Oncology
Quiz
Quiz: Durvalumab Plus Concurrent Chemoradiation Among PD-L1 Positive Patients With SCLC
08/29/2022
Among patients with limited-stage SCLC, did patients in the PD-L1 positivity group of a phase 2 study published in the European Journal of Cancer experience longer PFS and OS vs patients who were PD-L1 negative when treated with durvalumab...
Among patients with limited-stage SCLC, did patients in the PD-L1 positivity group of a phase 2 study published in the European Journal of Cancer experience longer PFS and OS vs patients who were PD-L1 negative when treated with durvalumab...
Among patients with...
08/29/2022
Oncology
Quiz
Quiz: Current First-Line Standard of Care for Extensive-Stage SCLC
07/25/2022
What treatment option in addition to platinum-based chemotherapy has become the current standard of care in the first-line setting for patients with extensive-stage small-cell lung cancer?
What treatment option in addition to platinum-based chemotherapy has become the current standard of care in the first-line setting for patients with extensive-stage small-cell lung cancer?
What treatment option in...
07/25/2022
Oncology
Quiz
Quiz: Does Next-Generation BAP1 Therapy Inhibit SCLC Cell Viability and Tumor Growth?
07/20/2022
According to study findings, does the recently developed therapy targeting SCLC BAP1 activity iBAP-II inhibit SCLC cell viability and tumor growth in vivo?
According to study findings, does the recently developed therapy targeting SCLC BAP1 activity iBAP-II inhibit SCLC cell viability and tumor growth in vivo?
According to study findings,...
07/20/2022
Oncology
Quiz
Quiz: Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Patients With SCLC and Intracranial Metastatic Disease
07/14/2022
According to systemic review and meta-analysis, when does stereotactic radiosurgery not prolong overall survival compared to whole brain radiotherapy in treatment of patients with small-cell lung cancer and intracranial metastatic disease?
According to systemic review and meta-analysis, when does stereotactic radiosurgery not prolong overall survival compared to whole brain radiotherapy in treatment of patients with small-cell lung cancer and intracranial metastatic disease?
According to systemic review and...
07/14/2022
Oncology
Quiz
Quiz: Which Combination Improved Overall Survival Among Patients With SCLC in the CAPSTONE-1 Trial?
05/24/2022
Findings from the CAPSTONE-1 trial found that the addition of which of the following drugs to chemotherapy significantly improved overall survival in patients with extensive-stage SCLC?
Findings from the CAPSTONE-1 trial found that the addition of which of the following drugs to chemotherapy significantly improved overall survival in patients with extensive-stage SCLC?
Findings from the CAPSTONE-1...
05/24/2022
Oncology
Test Your Knowledge
Quiz: Do Functional Biomarkers Play a Vital Role in SCLC Therapy?
02/24/2022
True or false: Discovering and targeting functional biomarkers for SCLC is crucial in understanding the molecular basis underlying tumorigenesis to better assist in improving clinical treatment.
True or false: Discovering and targeting functional biomarkers for SCLC is crucial in understanding the molecular basis underlying tumorigenesis to better assist in improving clinical treatment.
True or false: Discovering and...
02/24/2022
Oncology

Recent News

News
Lurbinectedin Demonstrates Promise As Second-Line Option for Patients With Platinum-Sensitive Small Cell Lung Cancer
12/18/2024
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results...
12/18/2024
Oncology
News
Chemoimmunotherapy Demonstrates Real-World Long-Term Efficacy for Patients With Extensive-Stage Small Cell Lung Cancer
12/10/2024
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a...
12/10/2024
Oncology
FDA Alerts
FDA Approves Durvalumab for Patients With Limited-Stage Small Cell Lung Cancer
12/05/2024
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the...
12/05/2024
Oncology
News
Addition of Talazoparib to Maintenance Atezolizumab Improves Survival Outcomes for Patients With SLFN11-Positive Extensive-Stage Small Cell Lung Cancer
12/04/2024
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results...
12/04/2024
Oncology
News
Addition of Toripalimab to First-Line Chemotherapy Improves Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/19/2024
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3...
11/19/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/04/2024
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...
According to results from a...
11/04/2024
Oncology
News
Adjuvant Durvalumab Significantly Extends Survival Among Patients With Limited-Stage Small Cell Lung Cancer
10/23/2024
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
According to results from the...
10/23/2024
Oncology
Conference Coverage
Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
10/09/2024
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis...
10/09/2024
Oncology
Conference Coverage
Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer
10/01/2024
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis...
10/01/2024
Oncology
News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use